Kieger Impact Healthcare Fund Class B CHF Accumulating

Reference Data

ISIN LU2488093530
Valor Number 119401713
Bloomberg Global ID
Fund Name Kieger Impact Healthcare Fund Class B CHF Accumulating
Fund Provider Kieger AG Kieger AG
Limmatstrasse 264, CH-8005 Zürich
Phone: +41 44 444 18 44
Web: https://kieger.com/
E-Mail: info@kieger.com
Fund Provider Kieger AG
Representative in Switzerland ACOLIN Fund Services AG
Zürich
Phone: +41 44 396 96 96
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved.
Peculiarities

Fund Prices

Current Price * 88.33 CHF 05.09.2024
Previous Price * 88.31 CHF 04.09.2024
52 Week High * 98.66 CHF 15.05.2024
52 Week Low * 79.97 CHF 09.11.2023
NAV * 88.33 CHF 05.09.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 73,165,228
Unit/Share Assets *** 8,989
Trading Information SIX

Performance

YTD Performance -3.31% 29.12.2023
05.09.2024
1 month +3.10% 05.08.2024
05.09.2024
3 months -7.06% 05.06.2024
05.09.2024
6 months -5.67% 05.03.2024
05.09.2024
1 year -6.00% 05.09.2023
05.09.2024
2 years -11.67% 20.03.2023
05.09.2024
3 years - -
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Pacira BioSciences Inc 3.94%
Penumbra Inc 3.93%
ResMed Inc 3.92%
Sage Therapeutics Inc 3.89%
Hikma Pharmaceuticals PLC 3.87%
Organon & Co Ordinary Shares 3.84%
Intra-Cellular Therapies Inc 3.83%
DexCom Inc 3.69%
Allogene Therapeutics Inc 3.69%
Centene Corp 3.67%
Last data update 30.04.2023

Cost / Risk

TER *** 1.22%
TER date *** 30.09.2023
Performance Fee ***
PTR
Max. Management Fee *** 1.00%
Ongoing Charges ***
SRRI ***
SRRI date *** 31.08.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)